fenfluramine has been researched along with Fasting Hypoglycemia in 4 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that CFS is mediated by changes in hypothalamopituitary function and so measured the adrenocorticotrophic hormone (ACTH), cortisol, growth hormone, and prolactin responses to insulin-induced hypoglycemia, and the ACTH, cortisol, and prolactin responses to serotoninergic stimulation with dexfenfluramine in nondepressed CFS patients and normal controls." | 7.69 | Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. ( Allain, T; Bearn, J; Butler, J; Coskeran, P; McGregor, A; Munro, N; Wessely, S, 1995) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 7.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| " We hypothesized that CFS is mediated by changes in hypothalamopituitary function and so measured the adrenocorticotrophic hormone (ACTH), cortisol, growth hormone, and prolactin responses to insulin-induced hypoglycemia, and the ACTH, cortisol, and prolactin responses to serotoninergic stimulation with dexfenfluramine in nondepressed CFS patients and normal controls." | 3.69 | Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. ( Allain, T; Bearn, J; Butler, J; Coskeran, P; McGregor, A; Munro, N; Wessely, S, 1995) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 3.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "Ritanserin is a new selective 5-HT2 blocker receptor agent." | 2.67 | Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration. ( Argenio, GF; Bernini, GP; Birindelli, R; Del Corso, C; Franchi, F; Luisi, M; Vivaldi, MS, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bearn, J | 1 |
| Allain, T | 1 |
| Coskeran, P | 1 |
| Munro, N | 1 |
| Butler, J | 1 |
| McGregor, A | 1 |
| Wessely, S | 1 |
| Bernini, GP | 2 |
| Argenio, GF | 2 |
| Vivaldi, MS | 2 |
| Del Corso, C | 2 |
| Birindelli, R | 1 |
| Luisi, M | 2 |
| Franchi, F | 2 |
| Sgrò, M | 1 |
| Turtle, JR | 1 |
| Burgess, JA | 1 |
1 trial available for fenfluramine and Fasting Hypoglycemia
| Article | Year |
|---|---|
Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration.
Topics: Adult; Blood Glucose; Female; Fenfluramine; Growth Hormone; Humans; Hypoglycemia; Insulin; Middle Ag | 1990 |
3 other studies available for fenfluramine and Fasting Hypoglycemia
| Article | Year |
|---|---|
Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome.
Topics: Adrenocorticotropic Hormone; Adult; Fatigue Syndrome, Chronic; Female; Fenfluramine; Growth Hormone; | 1995 |
Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Hypoglycemia; Insulin; Middle Aged; Obesity; Piperi | 1989 |
Hypoglycemic action of fenfluramine in diabetes mellitus.
Topics: Adipose Tissue; Antigens; Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterifi | 1973 |